Citadel Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Citadel Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-72,600	Closed	-$13.3M	–	15335
2021 Q2	$13.3M	Sell	72,600 -19,400	-21%	-$3.33M	﹤0.01%	2641
2021 Q1	$14.1M	Sell	92,000 -93,700	-50%	-$14.5M	﹤0.01%	2470
2020 Q4	$29M	Sell	185,700 -210,200	-53%	-$27M	0.01%	1431
2020 Q3	$45.3M	Sell	395,900 -32,000	-7%	-$3.45M	0.01%	928
2020 Q2	$48M	Buy	427,900 +170,800	+66%	+$18.1M	0.02%	828
2020 Q1	$23.1M	Buy	257,100 +20,400	+9%	+$2M	0.01%	1123
2019 Q4	$25.6M	Sell	236,700 -34,500	-13%	-$3.69M	0.01%	1265
2019 Q3	$26.6M	Buy	271,200 +133,500	+97%	+$15M	0.01%	1232
2019 Q2	$18M	Buy	137,700 +49,000	+55%	+$6.32M	0.01%	1516
2019 Q1	$12M	Sell	88,700 -129,000	-59%	-$16M	0.01%	1855
2018 Q4	$21.2M	Buy	217,700 +55,500	+34%	+$6.56M	0.01%	1195
2018 Q3	$22.5M	Sell	162,200 -27,000	-14%	-$3.39M	0.01%	1300
2018 Q2	$23.5M	Sell	189,200 -35,700	-16%	-$4.17M	0.01%	1171
2018 Q1	$25.1M	Sell	224,900 -75,500	-25%	-$9.02M	0.01%	961
2017 Q4	$35.9M	Buy	300,400 +95,800	+47%	+$11.7M	0.02%	796
2017 Q3	$28.7M	Buy	204,600 +51,300	+33%	+$6.97M	0.02%	854
2017 Q2	$18.7M	Buy	153,300 +87,800	+134%	+$10.2M	0.02%	1040
2017 Q1	$7.94M	Sell	65,500 -31,000	-32%	-$4M	0.01%	1610
2016 Q4	$11.8M	Buy	96,500 +47,600	+97%	+$5.82M	0.01%	1240
2016 Q3	$5.99M	Sell	48,900 -28,500	-37%	-$3.67M	0.01%	1811
2016 Q2	$9.04M	Buy	77,400 +15,900	+26%	+$2.26M	0.01%	1332
2016 Q1	$8.56M	Buy	61,500 +12,000	+24%	+$1.76M	0.01%	1321
2015 Q4	$9.44M	Sell	49,500 -33,400	-40%	-$5.83M	0.01%	1324
2015 Q3	$13M	Buy	82,900 +14,800	+22%	+$2.7M	0.01%	1171
2015 Q2	$12.3M	Sell	68,100 -24,000	-26%	-$4.14M	0.01%	1330
2015 Q1	$16M	Buy	92,100 +19,600	+27%	+$3.55M	0.02%	1115
2014 Q4	$13.4M	Buy	72,500 +600	+0.8%	+$111K	0.01%	1197
2014 Q3	$11.9M	Sell	71,900 -8,100	-10%	-$1.33M	0.01%	1241
2014 Q2	$12.5M	Sell	80,000 -18,900	-19%	-$2.98M	0.01%	1101
2014 Q1	$15M	Sell	98,900 -800	-0.8%	-$127K	0.02%	1015
2013 Q4	$13.3M	Buy	99,700 +45,700	+85%	+$5.48M	0.02%	1041
2013 Q3	$6.27M	Sell	54,000 -20,200	-27%	-$2.22M	0.01%	1416
2013 Q2	$6.84M	Buy	+74,200	New	+$7.15M	0.01%	1306

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Citadel Advisors's ALXN Position: Q3 2021 in Review

Citadel Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 3,248,848 shares — an estimated $597M sold.

Citadel Advisors first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $597M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Citadel Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Citadel Advisors sold 3,248,848 Alexion Pharmaceuticals shares in Q3 2021, an estimated $597M.
Citadel Advisors first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
Citadel Advisors's Alexion Pharmaceuticals position peaked at $597M in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Citadel Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.